The pioglitazone treatment shows the ability to treat steatohepatitis and improve insulin sensitivity while acknowledging its potential use as a secondary treatment for diabetic MASH patients, but also its inability to resolve fibrosis. Here, INS is linked to metabolic dysfunction-associated steatohepatitis.